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Background: The focus of this study was to assess the impact of lymphovascular invasion (LVI) on both the
recurrence of cancer and the long-term survival of Chinese patients with resectable gastric cancer (GC).
Methods: A retrospective analysis of the clinicopathological data for 1148 GC patients who had undergone
gastrectomy with regional lymphadenectomy was performed. The primary objective was to assess the correlation
between LVI and post-surgery outcomes for each patient. This was done by routine H & E staining for LVI on
patients’ disease-free survival (DFS) and disease-specific survival (DSS).
Results: LVI was detected in 404 (35.2%) of the 1148 GC patients. The presence of LVI was significantly correlated
with the level of CA19-9, the tumor size, the Lauren classification, tumor differentiation, gastric wall invasive depth,
lymph node involvement, distant metastasis and an advanced TNM stage. There was a lower DFS and DSS in the
patients with LVI as compared to the patients without LVI. A multivariate analysis also identified LVI as an independent
prognostic factor of both DSS and DFS.
Conclusions: The presence of LVI is a risk factor for the recurrence of cancer and an independent indicator of a poor
outcome in GC patients following surgery. The LVI status should be taken into consideration when determining the
best approach for the treatment of the individual.
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Gastric cancer (GC) continues to be a major challenge
in the health care community worldwide especially in
East Asian countries; such as China, South Korea and
Japan [1,2]. Despite the advances in medical treatments,
gastrectomy with regional lymphadenectomy remains
the primary treatment for patients with resectable GC
and has a five-year overall survival (OS) rate of approxi-
mately 20-30%. The low OS rate is due to the high fre-
quency in the post-surgery recurrence of cancer [3,4].* Correspondence: liyuanf@sysucc.org.cn; caimuyan@hotmail.com
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unless otherwise stated.The most reliable indication of the prognosis following
surgery can be provided through the assessment of the GC
using the International Union Against Cancer/American
Joint Committee on Cancer (UICC/AJCC) TNM staging
guidelines [5]. However, it has been noted that many pa-
tients that have been determined to have the same UICC/
AJCC TNM stage have heterogeneous survival rates.
Therefore, there has been an increased focus on determin-
ing other prognostic indicators that will aid in the identifi-
cation of GC patients with a higher risk for the recurrence
of their cancer and who may be candidates for other adju-
vant therapies.
The major factor contributing to the recurrence of
cancer and mortality is thought to be the systemic dis-
semination of cancer cells. Lymphovascular invasionis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Correlation between lymphovascular invasion
and clinicopathologic characteristics in gastric carcinoma
Variables Lymphovascular invasion
All cases Absence Presence P value*
Sex 0.955
Female 354 229 (64.7%) 125 (35.3%)
Male 794 515 (64.9%) 279 (35.1%)
Age at diagnosis (years) 0.458
<60 574 378 (65.9%) 196 (34.1%)
≥60 574 366 (63.8%) 208 (36.2%)
CEA† 0.665
Normal 791 525 (66.4%) 266 (33.6%)
Elevated 157 107(68.2%) 50 (31.8%)
CA19-9‡ 0.004
Normal 707 487 (68.9%) 220 (31.1%)
Elevated 195 113 (57.9%) 82 (42.1%)
Size (diameter), cm <0.0001
≤5 697 487 (69.9%) 210 (30.1%)
>5 451 257 (57.0%) 194 (43.0%)
Lauren classification 0.004
Diffuse 585 356 (60.9%) 229 (39.1%)
Mixed/ Intestinal 563 388 (68.9%) 175 (31.1%)
Differentiation <0.0001
Well/moderate 435 331 (76.1%) 104 (23.9%)
Poor/undifferentiated 713 413 (57.9%) 300 (42.1%)
Gastric wall invasion <0. 0001
T1/T2 150 140 (93.3%) 10 (6.7%)
T3/T4 998 604 (60.5%) 394 (39.5%)
Nodal metastasis <0.0001
N0 377 322 (85.4%) 55 (14.6%)
N1-N3 771 422 (54.7%) 349 (45.3%)
Distant metastasis <0.0001
M0 1003 679 (67.7%) 324 (32.4%)
M1 145 65 (44.8%) 80 (55.2%)
TNM stage <0.0001
I/II 486 409 (84.2%) 77 (15.8%)
III/ IV 662 335 (50.6%) 327 (49.4%)
*Chi-square test; †Preoperative serum CEA was measured in 948 patients;
‡Preoperative serum CA19-9 was measured in 902 patients; CEA indicates
carcinoembryonic antigen; CA19-9 indicates carbohydrate antigen 19-9.
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invasion, is the presence of tumor cells within the lumen
of the blood and/or lymphatics; the process of which
leads to circulating tumor cells. The presence of LVI is a
common pathological finding in a variety of human can-
cers and has been shown to be associated with a high re-
currence rate and poor prognosis in patients with breast
cancer, colorectal cancer, non-small cell lung cancer and
clear cell renal cell carcinoma [6-10]. The combination
of traditional TNM staging with an assessment for LVI
could lead to a more accurate indication of the patient’s
prognosis [11].
Previous studies have investigated the prognostic sig-
nificance of LVI in relation to GC in small selected co-
horts. The results of these studies indicated that the
presence of LVI, either in the blood or lymphatics, corre-
lated with tumor recurrence and a low survival rate that
appeared to be independent of lymph node status
[8,12-18]. The prognostic value of an LVI assessment in
GC remains controversial due to the small number of
participants in the study. To address this issue, a large
retrospective study of GC patients who had undergone
surgery in Southern China was designed and carried out
to thoroughly investigate the correlation between LVI
and cancer-recurrence/ long-term survival.
Methods
Patient selection
Of the 3321 GC patients that had undergone surgery in
Sun Yat-sen University Cancer Center (Guangzhou,
China) between May of 1996 and June of 2009, 1148
(34.6%) were selected because they had a gastrectomy
with lymphoadenectomy. This was determined using the
archives of the Department of Pathology based upon the
following criteria: (1) a histologically confirmed primary
gastric adenocarcinoma; (2) no neoadjuvant treatment
before operation; (3) complete resection of the tumor;
(4) resection margins were negative; (5) detailed and
complete follow-up data.
Variables included the gender of the patient (female
and male), age at the time of surgery (<60 and ≥ 60
years), the level of preoperative serum carcinoembryonic
antigen (CEA; elevated and normal), levels of the carbo-
hydrate antigen (CA19-9; elevated and normal), approxi-
mate tumor size (≤5 and > 5cm), tumor differentiation
(well, moderate and poor), Lauren classification (intes-
tinal, mixed and diffuse), infiltration depth (T1, T2, T3
and T4), lymph node status (N0, N1, N2 and N3), dis-
tant metastasis (absent and presence), TNM stage (I, II,
III and IV), LVI (absent and presence) and recurrence.
Detailed information is given in Table 1. The immunora-
diometric method was used to measure the serum con-
centrations of both CEA and CA19-9. The cut-off values
for CEA and CA19-9 were 5.0 ng/ml and 35.0 U/ml;serum concentrations found to be above these respective
cut-off values were defined as elevated. In the first year
post surgery patients were followed up every three
months; the following two years they were seen every six
months and annually thereafter. A complete history and
physical examination, gastroscopy, gastrointestinal barium
examination, CT and MRI was done in order to assess
tumor recurrence; which was defined as local recurrence
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as the time interval post-surgery until recurrence/metasta-
sis or death from gastric cancer (GC), whichever came
first. The disease-specific survival (DSS) was defined as
the time interval post-surgery until the date of death
resulting from GC or the date of the last follow-up exam.
This study was approved by the Institute Research Med-
ical Ethics Committee of Sun Yat-sen University Cancer
Center. All patient information was hidden to reviewers.
No informed consent, written or verbal, was obtained for
the retrospective use of the tissue specimens from the pa-
tients in this study, however, since most were deceased ap-
proval was deemed unnecessary by the Ethics Committee
and the need for consent was waived.
Pathological evaluation
Standard pathological procedures were followed in the
processing of all surgical specimens. H & E-stained
slides of the primary tumors and regional lymph nodes
were independently examined by two pathologists; both
of whom had no prior knowledge of the clinical parame-
ters of the patient. Discrepancies were resolved through
the simultaneous re-examination of the slides using a
double-headed microscope by both pathologists. For
each tumor, there were at least three slides available for
pathological evaluation. The WHO Classification of Tu-
mours of the Digestive System (2010 version) was used
to determine tumor differentiation. The depth of tumor
infiltration, the lymph node status and the tumor stage
was determined utilizing the UICC/AJCC TNM (tumor-
node-metastasis) Classification System (2010 version).
LVI was defined as the invasion of vessel walls by tumor
cells and/or the presence of tumor emboli within an
endothelial-lined space; with no distinction between vas-
cular and lymphatic vessels [8]. The following criterion
was used to identify the lumen of blood and/or lymph
vessels: (i) lined by endothelium; (ii) with supporting
smooth muscle or elastica; (iii) filled with lymphatic fluid
or red blood cells. Alternative circumstances wereFigure 1 Histological patterns of lymphovascular invasion in gastric c
were observed within an endothelium-lined space.considered artifacts due to peritumoral edema and tissue
shrinkage.
Statistical analysis
The Chi-square test was used in order to identify the
correlation between LVI and clinicopathologic variables
in GC patients. Both DFS and DSS were calculated using
the Kaplan-Meier method and the differences between
the patient groups were analyzed utilizing a log-rank test
in a univariate analysis. A Cox proportional hazard
model was utilized for a multivariate analysis in order to
determine independent prognostic factors. All tests were
two sided and a P value of < 0.05 was considered to be
statistically significant. Statistical analyses were performed
using The SPSS 16.0 statistical software (SPSS, Chicago,
IL, USA).
Results
Clinicopathologic characteristics in patients with
resectable GC
The clinicopathological features of our GC cohort are
detailed in Table 1. A total of 1148 patients; with a
male-to-female ratio of 2.24:1, were included in the
present study. The median age at the time of resection
was 59.0 years (range, 18.0 to 84.0 years). The presence
of LVI was detected in 404 patients (35.2%); LVI was
identified as the invasion of vessel walls by tumor cells
(Figure 1A) and/or the presence of tumor emboli within
an endothelial-lined space (Figure 1B).
The correlation of LVI with clinicopathologic
characteristics in patients with resectable GC
The correlation between LVI and clinicopathologic char-
acteristics is shown in Table 1. Our analyses support a
significant correlation between the presence of LVI and
the level of CA19-9, tumor size, Lauren classification,
tumor differentiation, infiltration depth, lymph node in-
volvement, distant metastasis and TNM stage (P = 0.004
for CA19-9 level and Lauren classification; P < 0.0001ancer. (A) Vessel walls were invaded by tumor cells. (B) Tumor emboli
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found between the presence of LVI and other variables;
such as gender, age and CEA level (P > 0.05).
The prognostic impact of LVI in patients with resectable GC
The average time interval between surgery and the
follow-up examination was 40.4 months (range, 1.0 to
161.5 months). The five-year DSS and DFS rates for all
1148 patients were 51.0% and 44.6%. The five-year DSS
was determined to be 33.1% in patients with LVI and
60.4% in patients without LVI; as determined using the
log-rank test analysis which also indicated that there was a
significant difference between the two groups (P < 0.0001)
(Figure 2A) The analysis also indicated that DFS was
significantly decreased in patients with LVI as com-
pared to those without LVI (27.8% vs. 53.1%, P < 0.0001)
(Figure 2B). A stratified analysis was performed to evalu-
ate the correlative impact of identifying LVI at each TNM
stage as it relates to patient survival. Our results indicate
that the presence of LVI was a reliable prognostic factor
for DSS in GC patients with stage I, stage II, stage III or
stage IV (P < 0.05, Figure 3A-D). Similar results were ob-
tained when focusing on DFS. LVI was determined to be a
reliable indicator of DFS in stage I or stage III (P = 0.005
for both) and showed a tendency towards statistical sig-
nificance when found in stage II (P = 0.086) or stage IV
(P = 0.067), as determined by doing a stage-match sur-
vival analysis (Figure 3E-H).
LVI is an independent predictor of poor outcome in
patients with resectable GC
The univariate analysis indicated that certain variables
were shown to correlate with DSS; these variables in-
clude age at the time of surgery (P = 0.046), CA19-9 level
(P = 0.001), tumor size (P < 0.0001), Lauren classification
(P < 0.0001), tumor differentiation (P < 0.0001), infiltrationFigure 2 The impact of lymphovascular invasion on the prognosis of
significant difference in the disease-specific survival (A) and disease-free su
-negative patients.depth (P < 0.0001), lymph node metastasis (P < 0.0001),
distant metastasis (P < 0.0001), TNM stage (P < 0.0001)
and LVI (P < 0.0001, Table 2). A Cox proportional hazard
model was performed using the multivariate analysis in
order to determine independent prognostic factors of
DSS. The independent variables shown to correlate with
the post-surgical DSS were confirmed to be the tumor size
(HR, 1.311; 95%CI, 1.077-1.595, P = 0.007), infiltration
depth (HR, 2.284; 95%CI, 1.413-3.691, P = 0.001), distant
metastasis (HR, 2.365; 95%CI, 1.851-3.022, P < 0.0001),
TNM stage (HR, 2.090; 95%CI, 1.462-2.988, P < 0.0001)
and LVI (HR, 1.438; 95%CI, 1.171-1.766, P = 0.001)
(Table 2). Similarly, LVI was found to be an independent
prognostic factor for DFS in GC patients after curative
resection (HR, 1.393; 95%CI, 1.150-1.688, P = 0.001,
Table 3).
Discussion
The presence of LVI, a common pathological finding for
a variety of different cancer types, has been of consider-
able interest in the last few decades as a potential bio-
marker. The effectiveness of LVI as a reliable indicator
of cancer recurrence and prognosis has been clearly
established for both hepatocellular carcinoma and tes-
ticular cancer, supporting its incorporation into the
UICC/AJCC TNM staging system [19,20]. Previous stud-
ies have also shown that the presence of LVI correlated
with a poor prognosis. However, due to the lack of large,
well-designed and prospective studies, at this time LVI is
only recommend to be included in final pathological re-
ports rather than being included in the initial TNM sta-
ging system of GC as stated in the NCCN Guidelines for
Gastric Cancer of 2013 [21].
In this large-scale retrospective study, through the use
of H & E staining, LVI was determined to be present in
resected GC specimens at a fairly high frequency. Itspatients with gastric cancer (log-rank test). There was a statistically
rvival (B) between lymphovascular invasion-positive and
Figure 3 (See legend on next page.)
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Figure 3 The prognostic significance of lymphovascular invasion in patients stratified by the TNM stage (log-rank test). Stage-match
survival analysis showed that the presence of LVI was a prognostic factor for DSS in GC patients with stage I, stage II, stage III or stage IV (A-D).
Stage-match survival analysis demonstrated that LVI was a statistically significant predictor for DFS in stage I or stage III and a tendency towards
statistical significance was found in stage II (P = 0.086) or stage IV (P = 0.067, E-H).
Table 2 Univariate and multivariate analyses of different prognostic factors in 1148 patients with gastric carcinoma for
disease-specific survival
Variable Univariate analysis* Multivariate analysis
All cases HR (95% CI) P value HR (95% CI) P value
Sex 0.800
Female 354 Reference
Male 794 0.977 (0.817-1.169)
Age at diagnosis (years) 0.046 1.170 (0.960-1.425) 0.120
≤59 574 Reference
>59 574 1.184 (1.003-1.398)
CEA† 0.082
Normal 791 Reference
Elevated 157 1.231 (0.974-1.556)
CA19-9‡ 0.001 1.098 (0.878-1.374) 0.411
Normal 707 Reference
Elevated 195 1.438 (1.155-1.791)
Size (diameter), cm <0.0001 1.311 (1.077-1.595) 0.007
≤5 697 Reference
>5 451 1.695 (1.436-2.000)
Lauren classification <0.0001 0.836 (0.619-1.129) 0.243
Diffuse 585 Reference
Mixed/ Intestinal 563 0.740 (0.627-0.875)
Differentiation <0.0001 1.126 (0.816-1.554) 0.471
Well/moderate 435 Reference
Poor/undifferentiated 713 1.445 (1.211-1.724)
Gastric wall invasion <0.0001 2.284 (1.413-3.691) 0.001
T1/T2 150 Reference
T3/T4 998 4.643 (3.083-6.991)
Nodal metastasis <0.0001 0.806 (0.573-1.134) 0.216
N0 377 Reference
N1-N3 771 2.529 (2.061-3.102)
Distant metastasis <0.0001 2.365 (1.851-3.022) <0.0001
M0 1003 Reference
M1 145 3.479 (2.832-4.272)
TNM stage <0.0001 2.090 (1.462-2.988) <0.0001
I/II 486 Reference
III/ IV 662 3.039 (2.516-3.670)
Vascular invasion <0.0001 1.438 (1.171-1.766) 0.001
Absent 744 Reference
Present 404 2.121 (1.795-2.506)
*Cox regression model; †Preoperative serum CEA was measured in 948 patients; ‡Preoperative serum CA19-9 was measured in 902 patients; HR indicates hazards
ratio; CI indicates confidence interval; CEA indicates carcinoembryonic antigen; CA19-9 indicates carbohydrate antigen 19-9.
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Table 3 Univariate and multivariate analyses of different prognostic factors in 1148 patients with gastric carcinoma for
disease-free survival
Variable Univariate analysis* Multivariate analysis
All cases HR (95% CI) P value HR (95% CI) P value
Sex 0.936
Female 354 Reference
Male 794 1.007 (0.851-1.192)
Age at diagnosis (years) 0.359
≤59 574 Reference
>59 574 1.075 (0.921-1.255)
CEA† 0.068
Normal 791 Reference
Elevated 157 1.227 (0.985-1.528)
CA19-9‡ <0.0001 1.145 (0.929-1.411) 0.204
Normal 707 Reference
Elevated 195 1.499 (1.221-1.840)
Size (diameter), cm <0.0001 1.334 (1.111-1.602) 0.002
≤5 697 Reference
>5 451 1.643 (1.407-1.919)
Lauren classification 0.001 0.821 (0.619-1.090) 0.173
Diffuse 585 Reference
Mixed/ Intestinal 563 0.768 (0.657-0.897)
Differentiation <0.0001 1.085 (0.801-1.470) 0.598
Well/moderate 435 Reference
Poor/undifferentiated 713 1.374 (1.166-1.618)
Gastric wall invasion <0.0001 2.164 (1.416-3.308) <0.0001
T1/T2 150 Reference
T3/T4 998 4.450 (3.083-6.424)
Nodal metastasis <0.0001 0.788 (0.571-1.088) 0.148
N0 377 Reference
N1-N3 771 2.545 (2.106-3.075)
Distant metastasis <0.0001 2.259 (1.785-2.858) <0.0001
M0 1003 Reference
M1 145 3.544 (2.906-4.321)
TNM stage <0.0001 2.234 (1.596-3.127) <0.0001
I/II 486 Reference
III/ IV 662 3.062 (2.570-3.649)
Lymphovascular invasion <0.0001 1.393 (1.150-1.688) 0.001
Absent 744 Reference
Present 404 2.046 (1.749-2.394)
*Cox regression model; †Preoperative serum CEA was measured in 948 patients; ‡Preoperative serum CA19-9 was measured in 902 patients; HR indicates hazards
ratio; CI indicates confidence interval; CEA indicates carcinoembryonic antigen; CA19-9 indicates carbohydrate antigen 19-9.
Li et al. BMC Cancer  (2015) 15:370 Page 7 of 10presence was also shown to correlate with a higher chance
of cancer recurrence and was shown to be an independent
predictor of a poor survival rate in post-surgical GC
patients.The presence of LVI was detected in 35.2% of GC pa-
tients by H & E staining in this study. Similarly, del
Casar et al. had previously reported that 31.9% of GC
patients had presented with LVI as detected using H & E
Li et al. BMC Cancer  (2015) 15:370 Page 8 of 10staining complemented by immunostaining with CD34
[22]. However, a study by Kim et al. had indicated that
LVI was detected in 44.3% of GC patients by immuno-
staining with D2-40 and CD31 [16]. The differences in
the detection rate of LVI could be due to variations in
the detection methods. The use of H & E staining, an
elastic fiber stain and immunostaining are currently ac-
cepted methods in the literature for the detection of
LVI. Histological identification of LVI using H & E stain-
ing can be subjective, which could lead to the underesti-
mation of the incidence of LVI. However, successful
vessel identification using H & E staining has been previ-
ously shown to be sufficiently reliable. With quality con-
trol measures in place, the prognostic value of LVI as
detected by H & E staining was determined for upper
urinary tract urothelial carcinoma, breast cancer, colo-
rectal cancer and non-small cell lung cancer [11,23-25].
Additionally, a previous study indicated that both LVI
and BVI, as detected by both H & E and IHC staining,
significantly correlated with lymph node metastasis [17].
Consistent with previous findings, our data demon-
strates that the presence of LVI, as detected by H & E
staining, significantly correlates with DFS and DSS in
post-surgical GC patients.
Several small-scale studies have previously noted the
prognostic value of LVI on DSS and DFS in GC patients.
The presence of LVI was shown to be significantly asso-
ciated with a poorer OS in 77 patients with primary gas-
tric adenocarcinoma [22]. The three-year OS and three-
year DFS of 149 GC patients were found to be signifi-
cantly higher in GC patients without LVI as compared
to those with LVI [16]. A retrospective analysis indicated
that the OS of the LVI-positive patients, out of 436 stage
II GC patients, was shown to be worse than that of the
LVI-negative patients [26]. Similarly, we confirmed the
negative impact of LVI on DSS and DFS in a large co-
hort of 1148 patients with gastric adenocarcinoma who
underwent gastrectomy. Additionally, a stage-stratified
survival analysis determined that the presence of LVI in
GC patients correlated with a poorer prognostic out-
come. Notably, our study identified LVI as an independ-
ent prognostic factor through the use of multivariate
analysis. Our findings are in agreement with the results
of previously published studies [18,26]. However, it is of
note to point out that LVI was not identified as an inde-
pendent prognostic factor in GC patients in all of the pre-
vious studies identified. Kim et al. had reported that the
presence of LVI was shown to have a significant impact
on patient survival; however, it was not determined to be
an independent prognostic factor in GC. A close relation-
ship between the presence of LVI and tumor progression
was speculated to be the basis for this negative result [16].
This study, along with previous reports, supports the
view that the presence of LVI in GC is a promisingindicator of tumor aggressiveness; providing additional
information regarding the risk of cancer recurrence and
mortality. The addition of LVI assessment to the current
UICC/AJCC TNM staging system may lead to a more
accurate risk stratification of affected patients and may
lead to more appropriate clinical decision-making. Inter-
estingly, randomized controlled trials have recently dem-
onstrated treatment benefits from adjuvant therapy
given to GC patients who have undergone surgery
[4,27,28]. This supports the idea that GC patients with
LVI may be good candidates for further adjuvant therap-
ies that may improve their chances at survival.
The status of nodal metastasis was not evaluated as a
statistically significant prognostic factor in multivariate
analysis in the present study. However, nodal metastasis
was found to be closely correlated with a poor prognosis
in our univariate analysis on patient survival. Lymph
node status, TNM stage and LVI were included in our
multivariate analyses for DSS and DFS. It is known that
the status of nodal metastasis is included in TNM sta-
ging for GC and there is a strong association between
nodal metastasis status and TNM stage. Meanwhile, in
agreement with previously published studies, our data
indicate that the status of nodal metastasis significantly
correlated with the presence of LVI in GC [12,22].
Therefore, the effect of covariate mainly contributes to
this negative result.
Consistent with previous studies, the 5-year DSS rate
in this study was determined to be approximately 51.0%
for all stages, 70.5% for stage I-II and 36.1% for stage III-
IV [29,30]. However, the published SEER data indicated
that in the United States, the 5-year relative survival for
GC was 28.3% for all stages, 64.1% for a localized stage,
28.8% for a regional stage. In fact, it has been suggested
that patients with GC have a more favorable prognosis
in Asia as compared to those in Europe and the US; a
variety of potential reasons have been proposed to
explain this. First, the survival advantage of the Asian
ethnicity continues to play a role even after being con-
trolled for using other well-known prognostic factors
[31,32]. Additionally, the higher surgical quality may
contribute to the increased survival rate in Asia; gastrec-
tomy with D2 lymphadenectomy is the standard treat-
ment for GC patients in China. Several clinical trials
also have also confirmed the survival benefit for D2
lymph node dissection [33]. Meanwhile, the high inci-
dence of GC in China has subsequently resulted in
highly experienced surgeons due to the vast number of
times they perform that particular surgery.
Several limitations that could affect the interpretation
of our results exist due to the retrospective nature of the
study. Potential bias was minimized through the use of
strict inclusion and exclusion criteria for patient selec-
tion as well as duplicate reviews for each pathologic
Li et al. BMC Cancer  (2015) 15:370 Page 9 of 10evaluation carried out according to the commonly used
unified international criteria. Further validation of our
results will require subsequent large-scale prospective
studies.
Conclusions
Routine H & E staining to determine LVI could be an ef-
fective tool in the identification of GC patients that are
at an increased risk of tumor recurrence and/or progres-
sion. This could also aid in the selection of the appropri-
ate treatment for each patient depending on their status;
such as favoring adjuvant therapies in patients with LVI.
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